United Therapeutics (UTHR) Cash & Equivalents (2009 - 2026)

United Therapeutics has disclosed Cash & Equivalents across 18 years of filings, most recently posting $1.8 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 13.19% year-over-year to $1.8 billion; the TTM figure through Jun 2026 stood at $1.8 billion (up 13.19% YoY), while the FY2025 annual figure was $1.6 billion, down 8.25% from the prior year.
• Cash & Equivalents came in at $1.8 billion for Q2 2026 at United Therapeutics, up from $1.3 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.9 billion in Q1 2025 to a low of $795.2 million in Q2 2022.
• Average Cash & Equivalents over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2024.
• Year-over-year, Cash & Equivalents jumped 51.81% in 2025 and sank 32.64% in 2026.
• Over 5 years, Cash & Equivalents stood at $961.2 million in 2022, then climbed by 25.65% to $1.2 billion in 2023, then soared by 40.53% to $1.7 billion in 2024, then dropped by 8.25% to $1.6 billion in 2025, then grew by 15.81% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.8 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.6 billion in Q4 2025.